Cytori To Raise $6.0 Million in Strategic Equity Agreement with Green Hospital Supply.

SAN DIEGO -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (Frankfurt:XMPA) entered into a strategic equity agreement with Green Hospital Supply, Inc. (TOKYO:3360), one of the leading medical equipment suppliers in Japan, who will purchase 1.0 million shares of Cytori common stock at $6.00 per share. The transaction will close on or about April 12, 2007, subject to satisfaction of customary closing conditions.

"With this equity position in Cytori, Green Hospital Supply is making its first strategic investment in the emerging field of regenerative medicine," said Mr. Kunihisa Furukawa, President of Green Hospital Supply. "We have the required infrastructure and consulting experience to effectively provide and integrate certain regenerative medicine technologies, which may include cell preservation services, to medical centers throughout Japan."

"This deal bolsters our cash position, adds another strategic financial partner who shares our vision for regenerative medicine, and allows us to maintain our focus on the development of therapeutic applications for the Celution[TM] System and its near-term launch in Europe," said Christopher J. Calhoun, chief executive officer of Cytori Therapeutics. "We have jointly identified future collaborative opportunities, which we look forward to further exploring."

About Green Hospital Supply, Inc.

Green Hospital Supply, Inc. (TOKYO:3360) operates three businesses, which offer one-stop solutions for medical institutions in Japan to optimize their hospital management. The Total Pack System business offers solutions to meet the needs of clients to open, relocate, add and/or renovate hospital facilities. Green Hospital Supply continues the client relationships by selling medical practice materials and consumables after hospitals start operations (Medical Supply Business), and supplying meals and medical-related services (Health Care Business). The Company strengthens ties with its clients by making them business partners to further expand the spectrum of businesses, for example, launching dispensing pharmacies near hospitals (Health Care Business). http://www.ghs-inc.co.jp

About Cytori Therapeutics

Cytori Therapeutics is developing and seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious chronic, and life threatening conditions. To provide these therapies, physicians remove a small amount of a patient's fat, also known as adipose tissue, and run it through Cytori's Celution[TM] System. This System quickly separates and concentrates stem and regenerative cells from adipose tissue so they may be quickly administered back to the patient about an hour later. This system will dramatically improve the way in which personalized cell-based therapies can be delivered to patients. www.cytoritx.com

Cautionary Statement Regarding Forward-Looking Statements 

This press release includes forward-looking statements regarding events, trends and prospects of our business, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, regulatory uncertainties, dependence on performance of third parties, and other risks and uncertainties described (under the heading "Risk Factors") in Cytori Therapeutics' Form 10-K annual report for the year ended December 31, 2005 and subsequent SEC filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.